Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2010 1
2012 1
2013 6
2014 6
2015 8
2016 11
2017 19
2018 36
2019 38
2020 47
2021 67
2022 50
2023 41
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

314 results

Results by year

Filters applied: . Clear all
Page 1
BRAF mutation in myeloid neoplasm: incidences and clinical outcomes.
Abuasab T, Mohamed S, Pemmaraju N, Kadia TM, Daver N, DiNardo CD, Ravandi F, Qiao W, Montalban-Bravo G, Borthakur G. Abuasab T, et al. Among authors: dinardo cd. Leuk Lymphoma. 2024 May 2:1-6. doi: 10.1080/10428194.2024.2347539. Online ahead of print. Leuk Lymphoma. 2024. PMID: 38696743
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Bataller A, et al. Among authors: dinardo cd. Haematologica. 2024 May 2. doi: 10.3324/haematol.2024.285057. Online ahead of print. Haematologica. 2024. PMID: 38695144 Free article.
Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
DiNardo CD, Roboz GJ, Watts JM, Madanat YF, Prince GT, Baratam P, de Botton S, Stein AS, Foran JM, Arellano ML, Sallman DA, Hossain M, Marchione DM, Bai X, Patel PA, Kapsalis SM, Garcia-Manero G, Fathi AT. DiNardo CD, et al. Blood Adv. 2024 Apr 19:bloodadvances.2023012302. doi: 10.1182/bloodadvances.2023012302. Online ahead of print. Blood Adv. 2024. PMID: 38640348
Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.
Gruszczynska A, Maiti A, Miller CA, Ramakrishnan SM, Link DC, Uy GL, Petti AA, Hayes K, DiNardo CD, Ravandi F, Ley TJ, Spencer DH, Gao F, Konopleva MY, Welch JS. Gruszczynska A, et al. Among authors: dinardo cd. Haematologica. 2024 Apr 11. doi: 10.3324/haematol.2022.281396. Online ahead of print. Haematologica. 2024. PMID: 38618679 Free article.
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
Bataller A, Gener-Ricos G, Almanza E, Chien KS, Urrutia S, Bazinet A, Rodriguez-Sevilla JJ, Hammond D, Sasaki K, Takahashi K, DiNardo CD, Ravandi F, Borthakur G, Kadia TM, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Bataller A, et al. Among authors: dinardo cd. Blood Adv. 2024 Mar 21:bloodadvances.2024012565. doi: 10.1182/bloodadvances.2024012565. Online ahead of print. Blood Adv. 2024. PMID: 38513082
Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms.
Chien KS, Ong F, Kim K, Li Z, Kanagal-Shamanna R, DiNardo CD, Takahashi K, Montalban-Bravo G, Hammond D, Sasaki K, Pierce SA, Kantarjian HM, Garcia-Manero G. Chien KS, et al. Among authors: dinardo cd. Cancer Med. 2024 Mar;13(5):e7093. doi: 10.1002/cam4.7093. Cancer Med. 2024. PMID: 38497538 Free PMC article.
314 results